Ratnakar Securities Pvt. Ltd.

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs

BSE3663.70-17.65 (-0.48 %)

PREV CLOSE ( ) 3681.35

OPEN PRICE ( ) 3680.00

BID PRICE (QTY) 3663.15 (12)

OFFER PRICE (QTY) 3666.70 (1)

VOLUME 3348

TODAY'S LOW / HIGH ( )3643.00 3690.40

52 WK LOW / HIGH ( )2730 3949

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 12-10 1990

Management Info

Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director

Registered Office

Address 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone 040 66966300

Email mail@divislabs.com

Website www.divislabs.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE, MCX

NEWS

16Nov Diviâ€™s Laboratories informs about di
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obliga..

06Nov Divi's Laboratories reports 29% fall i
Divi's Laboratories has reported results for second quarter ended Septem..

06Nov Divi's Laboratories informs about outc
Divi's Laboratories has informed that the Board of Directors of the Comp..

06Nov Divi's Laboratories shines despite rep
Divi's Laboratories is currently trading at Rs. 3514.80, up by 164.90 po..

Financials

in Millions

	QTR Sep 23	ANNUAL 23
Net Profit	3420	18081.5
Gross Profit	4640	23541
Operating Profit	5590	26966.9
Net Sales	18680	76253

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Wockhardt (BSE) 391.00 (16.51%)	M.Cap ( in Cr)4903.05
Strides Pharma Scien (BSE) 543.75 (6.28%)	M.Cap ( in Cr)5097.36
Glenmark Pharma (BSE) 825.80 (3.78%)	M.Cap ( in Cr)23391.74
Fredun Pharma (BSE) 868.05 (3.54%)	M.Cap ( in Cr)405.07
Abbott India (BSE) 22879.50 (0.11%)	M.Cap ( in Cr)48631.15

Shareholding Pattern

	FI/BANKS/INSURANCE	7.35%
	PROMOTERS	51.93%
	MUTUAL FUNDS/UTI	13.62%
	NON-INSTITUTION	11.73%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Nippon India Nifty ...	9.29
ICICI Pru Nifty Pha...	9.17
Axis NIFTY Healthcare ETF	8.01
ICICI Pru Nifty Hea...	8.01
Aditya Birla SL Nif...	8.01
SBI Healthcare Opp ...	7.31

attention investors
kyc
ipo
ibt trading

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

DIVI'S LABORATORIES LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES